Floatz logo

h3b-6545

ER Positive

Eisai Inc.Phase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the ER Positive cohort.

Asset / SponsorPhaseRating
Capivasertib
Imperial College London
Phase 2BB

Same molecule, other indications

h3b-6545 is also rated in:

breast neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
Estrogen Receptor Positive TumorDormant
CCC
Indicative ·
52 / 100
View asset →
breast adenocarcinomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →